Nicholson Nur 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 21, 2026
Research Summary
AI-generated summary of this filing
Apellis (APLS) CTO Nicholson Nur Sells 2,203 Shares
What Happened
Nicholson Nur, Chief Technical Officer of Apellis Pharmaceuticals (APLS), sold 2,203 shares on January 20, 2026 at $19.79 per share, generating proceeds of $43,604. The filing shows this sale was to cover tax withholding on Restricted Stock Units (RSUs) that vested on January 16, 2026 — a routine disposition rather than a standalone investment decision.
Key Details
- Transaction date and price: 2026-01-20, 2,203 shares at $19.79 each (total $43,604)
- Transaction type: Sale (open market or private sale) executed to satisfy tax withholding obligations
- Footnote: Shares sold to cover tax withholding on RSUs released Jan 16, 2026 (Footnote F1)
- Shares owned after transaction: Not disclosed in the provided filing excerpt
- Filing timeliness: Report filed on Jan 21, 2026 (within normal Form 4 reporting window)
Context
Sales to cover tax withholding for vested RSUs are common and typically reflect routine administrative needs rather than a view on the company's prospects. For retail investors, purchases usually carry more signal value than routine withholding sales; this transaction should be viewed in that context.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-01-20$19.79/sh−2,203$43,604→ 78,843 total
Footnotes (1)
- [F1]This represents shares sold to cover tax withholding on the Restricted Stock Units released on January 16, 2026.